|Bid||4.7700 x 1200|
|Ask||5.2200 x 1400|
|Day's Range||4.9300 - 5.0500|
|52 Week Range||4.8600 - 9.2000|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
RedHill Biopharma will end its commercialization agreements with Entera Health and Advanz Pharma Corp.
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
A Triangle company's long-anticipated FDA approval has arrived, meaning the company is poised to start commercialization efforts it hopes will net a profit.
RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration, sending its shares up 25%. The drug, Talicia, is an oral capsule comprising two antibiotics, amoxicillin and rifabutin, as well as omeprazole, a common treatment for heartburn. The Israel-based company said the drug was designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies.
The U.S. Food and Drug Administration has approved RedHill Biopharma Ltd's drug to treat infections caused by bacteria known as Helicobacter pylori, the Israel-based company said on Monday. RedHill expects to launch the drug, Talicia, in the United States in the first quarter next year. Helicobacter pylori infection affects over 50% of the population worldwide, according to Redhill, and is one of the strongest risk factor for the development of gastric cancer.
The FDA worked overtime in October , deciding on the fate of several therapies and treatment options. Most reviews produced positive outcomes. Three new molecular entities, or NMEs, were approved in October, ...
Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc (NASDAQ: BIIB )'s about-face with respect to its Alzheimer's drug ...
On the eve of a Triangle drugmaker's approval for its lead candidate, it has struck a deal with a major pharmaceutical company for $36 million and rights to a new drug – selling off about 20 percent of its stock in the deal.
No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .